Advertisement
Research Article Free access | 10.1172/JCI112347
Find articles by Schapira, M. in: JCI | PubMed | Google Scholar
Find articles by Ramus, M. in: JCI | PubMed | Google Scholar
Find articles by Jallat, S. in: JCI | PubMed | Google Scholar
Find articles by Carvallo, D. in: JCI | PubMed | Google Scholar
Find articles by Courtney, M. in: JCI | PubMed | Google Scholar
Published February 1, 1986 - More info
In normal plasma, the serine protease inhibitor alpha 1-antitrypsin (alpha 1-AT) plays little or no role in the control of plasma kallikrein or activated Factor XII fragment (Factor XIIf), this function being performed by Cl-inhibitor. Recently, an alpha 1-AT variant was described with a Met----Arg mutation at the reactive center P1 residue (position 358) which altered the specificity of inhibition from the Met- or Val-specific protease neutrophil elastase to thrombin, an Arg-specific protease. We have now examined the inhibition of plasma kallikrein and Factor XIIf, both Arg-specific enzymes, with recombinant alpha 1-AT(Met358----Arg) produced by an Escherichia coli strain carrying a mutated human alpha 1-AT gene. The engineered protein was a very efficient inhibitor of both enzymes. It was more effective than Cl-inhibitor by a factor of 4.1 for kallikrein and 11.5 for Factor XIIf. These results suggest that recombinant alpha 1-AT(Met358----Arg) has therapeutic potential for disease states where activation of the plasma kinin-forming system is observed, for example in hereditary angioedema or septic shock.
Images.
Click on an image below to see the page. View PDF of the complete article